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***Dear Editor,***

Daidzein (7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one) is a naturally occurring compound commonly found in soybeans and some other legumes. Daidzein is an isoflavone by nature and isolated from *Pueraria Mirifica*, having category of biologically active secondary metabolites commonly produced in the soybean growth and belong to the group of flavonoids. A number of pharmacological activities have been accounted for daidzein, which includes anti-carcinogenesis, anti-fibrotic, anti-diabetic, cholesterol-lowering and cardiovascular activity. Daidzein pretreatment was found to diminish the seriousness of mucosal damage in a portion subordinate way. Some other therapeutic uses of daidzein are weight reduction, decreasing bowels moment, and inflammation associated with histopathological deformities (Amaral et al., 2017\[[@R1]\]). Their structure and function are alike to human estrogen, which can play a massive role in the prevention of osteoporosis, cancer, and postmenopausal syndromes. Uses of daidzein in anticancer activity against ovarian cancer are still limited (Meng et al., 2017\[[@R14]\]). Epidemiological data suggest that increased utilization of soybean in food results in decreased cancer risk. Soybean food is highly recommended in cancer prevention because it has a number of anticarcinogens (Yu et al., 2017\[[@R23]\]). The potent antioxidant activity of daidzein reported in various *in vitro*and*in vivo*studies was conclusively shown in this literature (Table 1[(Tab. 1)](#T1){ref-type="fig"}; References in Table 1: Amaral et al., 2017\[[@R1]\]; Atiq et al., 2019\[[@R2]\]; Budryn et al., 2018\[[@R3]\]; Chan et al., 2018\[[@R4]\]; Davis et al., 2001\[[@R5]\]; Eskra et al., 2019\[[@R6]\]; Foti et al., 2005\[[@R7]\]; Gundogdu et al., 2018\[[@R8]\]; Hua et al., 2018\[[@R9]\]; Huang et al., 2019\[[@R10]\]; Karale and Kamath, 2017\[[@R11]\]; Liang et al., 2018\[[@R12]\]; Medeiros et al., 2016\[[@R13]\]; Meng et al., 2017\[[@R14]\]; Murata et al., 2004\[[@R15]\]; Park et al., 2016\[[@R16]\]; Poschner et al., 2017\[[@R17]\]; Rigalli et al., 2019\[[@R18]\]; Rohrdanz et al., 2002\[[@R19]\]; Sivoňová et al., 2019\[[@R20]\]; Uifalean et al., 2018\[[@R21]\]; Wei et al., 2019\[[@R22]\]; Zheng et al., 2017\[[@R25]\]; Zheng et al., 2018\[[@R24]\]; Zhu et al., 2018\[[@R26]\]).
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